Boston Scientific Beheer
Beheer criteriumcontroles 3/4
De CEO Boston Scientific is Mike Mahoney, benoemd in Oct2011, heeft een ambtstermijn van 13.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 18.72M, bestaande uit 7.5% salaris en 92.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.12% van de aandelen van het bedrijf, ter waarde $ 156.52M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 8.6 jaar en 8.3 jaar.
Belangrijke informatie
Mike Mahoney
Algemeen directeur
US$18.7m
Totale compensatie
| Percentage CEO-salaris | 7.5% |
| Dienstverband CEO | 13.1yrs |
| Eigendom CEO | 0.1% |
| Management gemiddelde ambtstermijn | 8.6yrs |
| Gemiddelde ambtstermijn bestuur | 8.3yrs |
Recente managementupdates
Recent updates
Why The Fundamentals Make Me Bullish On Boston Scientific
Oct 31Boston Scientific Q3: Good Growth, But Not Good Enough To Justify Its P/E Ratio
Oct 23Is Boston Scientific (NYSE:BSX) A Risky Investment?
Oct 10
Slowing Rates Of Return At Boston Scientific (NYSE:BSX) Leave Little Room For Excitement
Sep 24Boston Scientific: Forward Returns Are Likely To Be Disappointing For Investors
Sep 20Boston Scientific Corporation's (NYSE:BSX) P/E Still Appears To Be Reasonable
Sep 09A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Aug 23The Strong Earnings Posted By Boston Scientific (NYSE:BSX) Are A Good Indication Of The Strength Of The Business
Aug 08Boston Scientific Q2 Earnings Preview: Can The Rally Continue?
Jul 17Here's Why We Think Boston Scientific (NYSE:BSX) Is Well Worth Watching
Jul 05Should You Investigate Boston Scientific Corporation (NYSE:BSX) At US$77.00?
Jun 21Boston Scientific Has Become A Standout Growth Story In Med-Tech
Jun 13Why We're Not Concerned About Boston Scientific Corporation's (NYSE:BSX) Share Price
Jun 08Is Boston Scientific (NYSE:BSX) Using Too Much Debt?
May 10Boston Scientific (NYSE:BSX) Is Reinvesting At Lower Rates Of Return
Apr 22Boston Scientific: Implications Of The Axonics-Medtronic Patent Clash
Apr 05A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Mar 26We Ran A Stock Scan For Earnings Growth And Boston Scientific (NYSE:BSX) Passed With Ease
Feb 29What You Can Learn From Boston Scientific Corporation's (NYSE:BSX) P/E
Feb 15Is Boston Scientific (NYSE:BSX) A Risky Investment?
Feb 02Boston Scientific (NYSE:BSX) Could Be Struggling To Allocate Capital
Jan 19Boston Scientific: Portfolio Updates Driving Top-Line Growth
Jan 17Boston Scientific: Continued M&A Drives More Growth
Jan 10Is Boston Scientific Corporation (NYSE:BSX) Worth US$56.1 Based On Its Intrinsic Value?
Dec 04Does Boston Scientific (NYSE:BSX) Have A Healthy Balance Sheet?
Nov 03Boston Scientific: Delivering Strong Growth, But Sector Derating Is A Big Issue
Oct 30ADVENT Offers Up An Early Present For Boston Scientific Investors
Aug 28Estimating The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Aug 24Boston Scientific (NYSE:BSX) Seems To Use Debt Quite Sensibly
Jul 25Boston Scientific Remains Operationally Sound But May Have Limited Upside
Jul 14Investors Could Be Concerned With Boston Scientific's (NYSE:BSX) Returns On Capital
Jul 10Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$2b |
| Jun 30 2024 | n/a | n/a | US$2b |
| Mar 31 2024 | n/a | n/a | US$2b |
| Dec 31 2023 | US$19m | US$1m | US$2b |
| Sep 30 2023 | n/a | n/a | US$1b |
| Jun 30 2023 | n/a | n/a | US$861m |
| Mar 31 2023 | n/a | n/a | US$846m |
| Dec 31 2022 | US$17m | US$1m | US$642m |
| Sep 30 2022 | n/a | n/a | US$596m |
| Jun 30 2022 | n/a | n/a | US$828m |
| Mar 31 2022 | n/a | n/a | US$754m |
| Dec 31 2021 | US$16m | US$1m | US$985m |
| Sep 30 2021 | n/a | n/a | US$1b |
| Jun 30 2021 | n/a | n/a | US$526m |
| Mar 31 2021 | n/a | n/a | US$201m |
| Dec 31 2020 | US$14m | US$667k | -US$115m |
| Sep 30 2020 | n/a | n/a | US$4b |
| Jun 30 2020 | n/a | n/a | US$4b |
| Mar 31 2020 | n/a | n/a | US$4b |
| Dec 31 2019 | US$16m | US$1m | US$5b |
| Sep 30 2019 | n/a | n/a | US$1b |
| Jun 30 2019 | n/a | n/a | US$1b |
| Mar 31 2019 | n/a | n/a | US$2b |
| Dec 31 2018 | US$14m | US$1m | US$2b |
| Sep 30 2018 | n/a | n/a | US$670m |
| Jun 30 2018 | n/a | n/a | US$521m |
| Mar 31 2018 | n/a | n/a | US$112m |
| Dec 31 2017 | US$13m | US$1m | US$104m |
Compensatie versus markt: De totale vergoeding ($USD 18.72M ) Mike } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 12.74M ).
Compensatie versus inkomsten: De vergoeding van Mike is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Mike Mahoney (59 yo)
13.1yrs
Tenure
US$18,723,735
Compensatie
Mr. Michael F. Mahoney, also known as Mike, has been Independent Director of CVS Health Corporation since November 01, 2023. He has been Chairman of Boston Scientific Corporation since May 3, 2016, and is...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman | 13.1yrs | US$18.72m | 0.12% $ 156.5m | |
| Executive VP & CFO | 10.8yrs | US$5.83m | 0.015% $ 20.2m | |
| Executive VP & Group President of Cardiology | 14.8yrs | US$5.59m | 0.011% $ 15.0m | |
| Executive VP & President of Peripheral Interventions | 11.8yrs | US$3.78m | 0.0019% $ 2.5m | |
| Executive VP and Group President of MedSurg & Asia Pacific | 8.3yrs | US$4.27m | 0.0016% $ 2.2m | |
| Executive Vice President of Global Operations | 2.5yrs | geen gegevens | 0.0025% $ 3.4m | |
| Senior VP | less than a year | geen gegevens | 0.00026% $ 346.6k | |
| Senior VP and Chief Information & Digital Officer | 8.9yrs | geen gegevens | geen gegevens | |
| Senior VP of Investor Relations | less than a year | geen gegevens | 0.0026% $ 3.4m | |
| Senior VP | 3.4yrs | geen gegevens | 0.0023% $ 3.1m | |
| Senior VP of Market Access & Chief Marketing Officer | 3.5yrs | geen gegevens | geen gegevens | |
| Executive Vice President of Human Resources | 11.9yrs | geen gegevens | 0.0022% $ 2.9m |
8.6yrs
Gemiddelde duur
56yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van BSX is doorgewinterd en ervaren (gemiddelde ambtstermijn van 8.6 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman | 12yrs | US$18.72m | 0.12% $ 156.5m | |
| Lead Independent Director | 10.7yrs | US$360.00k | 0.0030% $ 4.0m | |
| Independent Director | 8.6yrs | US$335.00k | 0.0033% $ 4.4m | |
| Independent Director | 8.3yrs | US$320.00k | 0.00020% $ 266.6k | |
| Independent Director | 3.4yrs | US$338.75k | 0.0027% $ 3.6m | |
| Director | less than a year | geen gegevens | geen gegevens | |
| Director | less than a year | geen gegevens | 0.00024% $ 319.9k | |
| Independent Director | 9.6yrs | US$326.25k | 0.0043% $ 5.7m | |
| Independent Director | 15.6yrs | US$340.00k | 0.0036% $ 4.8m | |
| Independent Director | 1.4yrs | US$233.23k | 0.00042% $ 559.9k | |
| Independent Director | 1.4yrs | US$233.23k | 0.00027% $ 359.9k |
8.3yrs
Gemiddelde duur
60.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van BSX wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.3 jaar).